Sinopharm Holding logo

Sinopharm Holding

Asia, Shanghai, China, Shanghai

Description

Sinopharm is the largest Chinese medical

Investor Profile

Sinopharm Holding has backed more than 1 startups, with 0 new investments in the last 12 months alone. The firm has led 0 rounds, about 0% of its total and boasts 2 exits across its portfolio.

Investment Focus Highlights

  • Concentrates on Series Unknown rounds (top funding stages).
  • Majority of deals are located in United States.
  • Strong thematic focus on Biopharma, Biotechnology, Health Care.

Stage Focus

  • Series Unknown (100%)

Country Focus

  • United States (100%)

Industry Focus

  • Biopharma
  • Biotechnology
  • Health Care
  • Life Science
  • Therapeutics
circle-line
FAQ

Frequently Asked Questions

Learn who this investor regularly partners with—both firms and angels—and explore their latest activity.

Who does Sinopharm Holding frequently co-invest with?

NS
North America, New York, United States, New York
Co-Investments: 1
Fosun Pharma
Asia, Shanghai, China, Shanghai
Co-Investments: 1
Apricot Capital
Asia, Shanghai, China, Shanghai
Co-Investments: 1
Humanwell
Asia, Hubei, China, Wuhan
Co-Investments: 1
Everbright
Asia, Hong Kong Island, Hong Kong, Wan Chai
Co-Investments: 1
HOPU Investment Management Company
Asia, Hebei, China, Xicheng
Co-Investments: 1

What are some of recent deals done by Sinopharm Holding?

Ambrx

La Jolla, California, United States

Ambrx is a clinical-stage biopharmaceutical company using expanded genetic code technology for next-gen therapies and immune modulation.

BiopharmaBiotechnologyHealth CareLife ScienceTherapeutics
Series UnknownAug 4, 2016
Amount Raised: $45,000,000